Comparative Pharmacology
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus KLEBCIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPICILLIN TRIHYDRATE versus KLEBCIL.
AMPICILLIN TRIHYDRATE vs KLEBCIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activity.
Klebcillin is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity, and activating autolytic enzymes.
250-500 mg PO q6h or 1-2 g IV/IM q4-6h; up to 12 g/day IV for severe infections.
KLEBCIL (ceftazidime-avibactam) 2.5 g (ceftazidime 2 g + avibactam 0.5 g) IV every 8 hours infused over 2 hours.
None Documented
None Documented
Terminal elimination half-life 1-1.8 hours; prolonged in renal impairment (up to 10-20 hours in anuria)
2-3 hours (prolonged to 30-60 hours in severe renal impairment; adjust dosing)
Renal: 75-90% unchanged; biliary: small amount; fecal: negligible
Primarily renal (70-80% unchanged); minor biliary/fecal (15-20%)
Category A/B
Category C
Penicillin Antibiotic
Penicillin Antibiotic